

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : A23L 1/30, 2/00	A1	(11) International Publication Number: WO 89/08405 (43) International Publication Date: 21 September 1989 (21.09.89)
(21) International Application Number: PCT/SE89/00114 (22) International Filing Date: 9 March 1989 (09.03.89) (31) Priority Application Number: 8800822-2 (32) Priority Date: 9 March 1988 (09.03.88) (33) Priority Country: SE (71)(72) Applicants and Inventors: MOLIN, Nils [SE/SE]; St. Mångatan 11 B, S-222 29 Lund (SE). ALBERTSSON, Carl-Erik [SE/SE]; Kristinavägen 40, S-131 50 Saltsjö-Duvnäs (SE). BENGMARK, Stig [SE/SE]; Box 5003, S-220 05 Lund (SE). LARSSON, Kåre [SE/SE]; Norra Villavägen 7 B, S-237 00 Bjärred (SE). (74) Agent: AWAPATENT AB; Box 5117, S-200 71 Malmö (SE).		(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US. Published <i>With international search report.</i> <i>With amended claims.</i>

(54) Title: NUTRIENT COMPOSITION AND METHOD FOR THE PREPARATION THEREOF

(57) Abstract

A nutrient composition for administration to patients in, for example, feeding by tube, or for use as a health drink is described. The nutrient composition comprises a fermented cereal-based product, enzyme and, optionally, further nutrient components, in combination with lactobacilli. Also described is a method of preparing a nutrient composition for administration to patients, inter alia in feeding by tube, or for use as a health drink, in which method a cereal flour is mixed with water, α -amylase and, optionally, a protease, the mixture is brought to the boil under agitation, allowed to cool and mixed with β -glucanase which is allowed to act until the viscosity of the mixture has decreased to below 0.020 Pas, whereupon the mixture is fermented.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

NUTRIENT COMPOSITION AND METHOD FOR
THE PREPARATION THEREOF

The present invention relates to a nutrient composition for administration to patients, inter alia for feeding by tube, and for use as a health drink, or as a nutrient for horses, as well as to a method for the
5 preparation of such a nutrient composition.

One medical problem in major operations of the abdomen is the general collapse of the organs due to infections from the large intestine. One way of reducing the risks of infections is to feed the patient
10 by tube, thereby to keep the intestine working. This method imposes special demands on the tube-administered nutrient. Not only must the nutrient be nutritively complete; it must also be so thin-bodied that it can be administered via a thin plastics catheter, without
15 necessitating a daily supply of more than 2-3 liters of liquid.

Furthermore, it is a great advantage if the nutrient can affect the composition of the patient's intestinal flora which frequently is disturbed in newly operated
20 patients, and this may sometimes result in symptoms of poisoning. This applies especially to patients who have been or are being treated with antibiotics.

A further field of application where there is a need for specific nutrients is horse-racing. Horses, under
25 stress, for example in connection with a race, frequently contract diarrhoea, which may affect their performance.

Present-day nutrient compositions used for feeding by tube substantially consist of fractionated food components recombined according to the recommendations
30 of dieticians. The known nutrient compositions suffer from a number of shortcomings. If they have a suitable low viscosity for administration through narrow tubes, their concentration of the requisite nutrients will

instead be too low, and therefore very large amounts must be given. Furthermore, the known nutrient compositions have a disagreeable taste and do not affect the patient's intestinal flora.

5 Indicia showing that certain intestine-specific lactobacilli have a special ability to counteract the establishment of undesired microorganisms in the intestine, have been reported by, for example, Wallström et al, 1987, J. Appl. Bacteriol. 62:513-520; Sherwood
10 et al, 1987, Lancet, Dec. 26, 1519.

It is an object of the present invention to provide a nutrient composition for administration to patients, inter alia in feeding by tube, or for use as a health
15 drink, said composition having a viscosity which is suitable for administration by tube, which is tasty, and which, furthermore, contains lactobacilli suitable for the intestine.

20 The nutrient composition according to the invention, especially when it contains fermented oats, is also highly suitable for administration to horses before a race for the prevention of diarrhoea.

A further object of the invention is to provide a method of preparing a nutrient composition for administration to patients, inter alia for feeding by
25 tube, or for use as a health drink.

The nutrient composition according to the invention comprises a fermented cereal-based product, enzymes and, optionally, further nutrient components, in combination with lactobacilli.

30 The method according to the invention is characterised in that cereal flour is mixed with water and α -amylase, and that the mixture is brought to the boil under agitation, allowed to cool and mixed with β -glucanase which is allowed to act until the viscosity
35 of the mixture has decreased to below 0.020 Pas, whereupon the mixture is fermented.

A patient who is fed by tube can be supplied with the suitable lactobacilli in basically three

different ways, viz. (i) the desired lactobacillus can be utilised for fermenting the product; (ii) a lactobacillus culture can be added separately to the fermented product; and (iii) the lactobacillus culture and the rest of the nutrient composition can be administered separately.

The lactobacillus desired in the final product is preferably used already for fermenting the product, whereby there is conveniently obtained a fermented product containing the desired culture, without necessitating the addition of further bacteria cultures.

The lactobacilli supplied not only have a favourable effect on the patient's intestinal flora; they also contribute to reducing the viscosity of the nutrient composition during the fermentation process. Proteins are degraded to short dextrans and amino acids. β -Glucanes are degraded by the enzyme β -glucanase. The result is a readily digested product which is rich in flavour and has adequate shelf life.

In the preferred embodiment, the fermenting ability of the lactobacilli is utilised, and at the same time the patient's need of viable lactobacilli is satisfied.

The lactobacillus cultures selected are special cultures which in vitro have certain characteristics significant to the contemplated use. Suitable cultures are obtained by extracting and isolating lactobacilli that have established themselves in the intestine of healthy persons. The following characteristics are taken into account in selecting a suitable production strain:

- the ability to ferment oat-flour
- the specific growth rate
- the ability to rapidly reduce pH during the fermentation process
- suitable final pH upon fermentation
- the acid fermentation pattern from glucose

- survival upon freeze-drying
- resistance to bile
- resistance to antibiotics
- plasmide contents
- 5 - the ability to spontaneously adhere to the intestine
- reuterine production in the presence of glycerol
- cholesterol interaction
- the ability to produce desirable flavouring agents
- the ability to degrade β -glucanes

10 All of these characteristics need not occur in one and the same culture, but it is recommended to choose a culture that has as many as possible of these characteristics.

A preferred culture is an isolate of intestine-specific *Lactobacillus reuteri* and a preparation of lipase
15 enzymes stimulating the production of antimicrobial substances (reuterine) by said *Lactobacillus*. Other useful organisms are, for example, *Lactobacillus fermentum*, *L. acidophilus*, *L. alimentarius*, *L. brevis* sp. *lindneri*,
20 *L. plantarum*, *L. leuconostoc* and *L. dextranicum*.

The basis of the nutrient composition is cereal flour. It has surprisingly been found that especially a suspension of oat-flour in water is an ideal basis
for lactic acid fermentation. Of all cereals, oat
25 has the best amino acid balance, and the lipid fraction contains the maximum amount of polar lipids. It has been shown, by works in progress, that this lipid type has a favourable effect on the gastric mucosa.

In countries in which there is a shortage of
30 oats, also other cereals, such as corn, may however be used.

In order to obtain a nutrient composition which is as complete as possible, the composition can be mixed with soya flour before fermentation to supplement
35 the protein and fat contents.

Furthermore, minerals and vitamin contents may be supplemented before or after fermentation.

In the method, the cereal flour is suspended in water, and α -amylase is added, either in the form of malt flour, pure α -amylase, or in the form of α -amylase-containing microorganisms. The suspension is brought to the boil under agitation to the suitable temperature which, if it is an oat suspension, is maximally 95°C. Then, the suspension is allowed to cool about 50°C, whereupon β -glucanase is added which is allowed to act for 1-2 hours at about 50°C, whereupon the viscosity has decreased to about 0.020 Pas.

The cereal flour can also be treated with various proteases in order to degrade the proteins therein.

It is recommended that the product be then enriched with soya flour.

Finally, the mixture is mixed with a suitable bacteria culture, preferably the lactobacillus culture that is to be present in the final composition, and fermented at a temperature that should lie between 30 and 40°C.

The composition according to the invention may be used either as it is, in the form of an aqueous solution, or the aqueous solution can be concentrated and diluted immediately before use. Such a solution has an estimated shelf life of about 8 days at cooling temperature.

Alternatively, the nutrient solution can be freeze-dried and then dissolved in water before use. An additionally improved shelf life is obtained if the cereal flour, preferably the oat-flour is defatted before use by extraction in a solvent, such as ethanol or supercritical carbon dioxide, whereupon the resulting oil, after emulsifying and spray-drying is recycled to the product after freeze-drying.

The method described above thus gives a fermented nutrient composition which is optimal for enteral nutrition and which contains physiologically active cells of a specially selected lactobacillus culture

in high concentration. Furthermore, the product gives a rapid colonisation in the small intestine.

The preferred freeze-drying imparts to the nutrient composition a much increased resistance to fat oxidation, whereby a satisfactory shelf life is obtained.

In two instances, the solution was administered to patients under intensive care for nutritional disorders and sepsis due to colonisation of aerobic intestinal bacteria. When the treatment began, both patients were apathetic because no previous treatment had proved successful. After administration of the nutrient solution according to the invention, containing lactobacilli, by tube to the intestine, both patients made a dramatic recovery.

The nutrient preparation according to the invention can be used also as a supplementary nourishment in general, for example in the form of a health drink.

The invention will now be described in more detail with reference to the following nonrestrictive Example.

EXAMPLE

34 g oat-flour (Mp oat-flour, product name) are suspended in 100 g water together with 3.4 g malt flour alternatively 1 g pure α -amylase. The oat-flour suspension is brought to the boil under agitation to 95°C, whereupon it is allowed to cool to about 50°C. Then, 1% β -glucanase (calculated on the amount of oat-flour) is added and allowed to act for 1-2 hours at 50°C, whereby the viscosity is decreased to about 0.020 Pas.

After that, the suspension is enriched with soya flour.

Finally, a lactobacillus culture is added, selected with due regard to the characteristics mentioned in the general part of the specification, whereupon the suspension is fermented at, for example, 37°C for 20 hours.

7

To further enrich the product, further fat, sodium, vitamin A, vitamin D, riboflavin, vitamin B₆, folic acid and ascorbic acid and, optionally, also potassium and calcium are added.

5 The product prepared in this manner has the energy and nutrient contents stated in Table 1.

TABLE 1

			<u>ENRICHMENT / 100 ml</u>	
			Alt. 1	Alt. 2
Recommended		Oat sus-	Skim milk	Soya flour
contents/100 ml		pension/100 ml	powder 3.7 g	2.8 g
Energy KJ	424	424 *	475 *	513 *
Protein g	4.7	3.4	4.7 *	4.7 *
Fat g	3.5	1.8	1.8	1.82
Carbohydr. g	11.8	16.6 *	18.5 *	17.6 *
Ca mg	>51	13.5	58.9 *	20.8
Fe mg	>0.94	1.32 *	2.46 *	1.62 *
P mg	70	98 *	133 *	116 *
Mg mg	>28 g	35 *	40 *	44 *
Na mg	80	1.25	21	1.28
K mg	148	84	150 *	134
ret. eqv. mg	> 0.05	-	0.011	0.0001
vit. D µg	> 0.28	-	traces	-
Thiamine mg	> 0.070	0.15 *	0.19 *	0.18 *
Ribofl. mg	> 0.094	0.037	0.11 *	0.04
vit. B ₆ mg	> 0.11	0.04	0.053	0.059
Folic acid µg	40	0.006	0.006	0.06
Ascorb. mg	> 3.3	-	0.3	-

* Satisfies demands for recommended amount of nutrition

CLAIMS

1. Nutrient composition, characterised in that it comprises a fermented cereal-based product, enzymes and, optionally, further nutrient components, in combination with lactobacilli.
- 5 2. Nutrient composition as claimed in claim 1, characterised in that the cereal-based product is a product based on oat-flour.
3. Nutrient composition as claimed in claim 1 or 2, characterised in that the cereal-based product is fermented with said lactobacilli.
- 10 4. Nutrient composition as claimed in claim 1 or 2, characterised in that the lactobacilli have been added to the composition after fermentation with another culture.
- 15 5. Nutrient composition as claimed in claim 1 or 2, characterised in that the lactobacilli are present in a form separate from the remainder of the composition.
- 20 6. A nutrient composition as claimed in one or more of the preceding claims, characterised in that the enzymes are α -amylase, β -glucanase and, optionally, a protease.
7. Nutrient composition as claimed in one or more of the preceding claims, characterised in that it comprises, as further nutrient components, soya flour and/or supplementary mineral substances and vitamins.
- 25 8. Nutrient composition as claimed in one or more of the preceding claims, characterised in that it is in the form of an aqueous solution or a freeze-dried powder.
- 30 9. A method of preparing a nutrient composition, characterised in that
- a cereal flour is mixed with water, α -amylase

and, optionally, a protease;

- the mixture is brought to the boil under agitation;
- is allowed to cool;
- is mixed with β -glucanase which is allowed to
- 5 act until the viscosity of the mixture has decreased to below 0.020 Pas; and
- is fermented.

10 10. A method as claimed in claim 9, characterised in that the cereal flour utilised is oat-flour.

11. A method as claimed in claim 9 or 10, characterised in that the mixture is fermented with lactobacilli.

15 12. A method as claimed in claim 9 or 10, characterised in that lactobacilli are admixed to the mixture after fermentation.

13. A method as claimed in one or more of claims 9-12, characterised in that soya flour is admixed to the mixture before fermentation.

20 14. A method as claimed in one or more of claims 9-13, characterised in that the mixture is enriched with supplementary mineral substances and vitamins before or after fermentation.

25 15. A method as claimed in one or more of claims 9-14, characterised in that the mixture is freeze-dried after fermentation.

30 16. A method as claimed in claim 15, characterised in that the cereal flour is defatted before it is mixed with water and α -amylase, and in that the removed fat after emulsifying and spray-drying is recycled to the freeze-dried composition.

AMENDED CLAIMS

[received by the International Bureau
on 20 July 1989 (20.07.89)]

original claims 1-16 replaced by amended claims 1-11 (3 pages)]

1. Nutrient composition which is optimal for enteral nutrition and which has a low viscosity, characterised in that it comprises an aqueous solution of a fermented product based on oat-flour, α -amylase, β -glucanase and, optionally, a protease and, optionally, further nutrient components, in combination with viable lactobacilli which have the ability to spontaneously adhere to the human intestine and which are isolated from the human intestine.

2. Nutrient composition as claimed in claim 1, characterised in that the lactobacilli have been selected to have as many of the following characteristics as possible:

- the ability to ferment oat-flour
- the specific growth rate
- the ability to rapidly reduce pH during the fermentation process
- suitable final pH upon fermentation
- the acid fermentation pattern from glucose
- survival upon freeze-drying
- resistance to bile
- resistance to antibiotics
- plasmide contents
- reuterine production in the presence of glycerol
- cholesterol interaction
- the ability to produce desirable flavouring agents
- the ability to degrade β -glucanes.

3. Nutrient composition as claimed in claim 1 or 2, characterised in that the oat-flour based product is fermented with said lactobacilli.

4. Nutrient composition as claimed in claim 1 or 2, characterised in that the lactobacilli have been added to the composition after fermentation with another culture.

5. Nutrient composition as claimed in one or more of the preceding claims, c h a r a c t e r i s e d in that it comprises, as further components, soya flour and/or supplementary mineral substances and vitamins.

6. Nutrient composition as claimed in one or more of the preceding claims, c h a r a c t e r i s e d in that it is in the form of a freeze-dried powder dissolved in water.

7. A method of preparing a nutrient composition which is optimal for enteral nutrition and which has a viscosity of 0.020 Pas at most, c h a r a c t e r i s e d in that

- an oat-flour is mixed with water, α -amylase and, optionally, a protease;
- the mixture is brought to the boil under agitation;
- is allowed to cool;
- is mixed with β -glucanase which is allowed to act until the viscosity of the mixture has decreased to below 0.020 Pas; and
- is fermented, preferably by using viable lactobacilli; which have the ability to spontaneous adhere to the human intestine and which have been isolated from the human intestine,

or, alternatively, if not used for the fermentation, said viable lactobacilli are added after fermentation.

8. A method as claimed in claim 7, c h a r a c t e r i s e d in that soya flour is admixed to the mixture before fermentation.

9. A method as claimed in claim 7 or 8, c h a r a c t e r i s e d in that the mixture is enriched with supplementary mineral substances and vitamins before or after fermentation.

10. A method as claimed in one or more of claims 7-9, c h a r a c t e r i s e d in that the mixture is freeze-dried after fermentation and then again dissolved in water before use.

11. A method as claimed in claim 10, c h a -
r a c t e r i s e d in that the oat-flour is defatted
before it is mixed with water and α -amylase, and in
that the removed fat after emulsifying and spray-drying
is recycled to the freeze-dried composition.

INTERNATIONAL SEARCH REPORT

International Application No PCT/SE89/00114

I. CLASSIFICATION F SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC ₄ <div style="margin-top: 10px;">A 23 L 1/30, 2/00</div>																							
II. FIELDS SEARCHED <div style="text-align: right; font-size: small;">Minimum Documentation Searched ⁷</div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <th style="width: 30%; text-align: left; padding: 5px;">Classification System</th> <th style="text-align: left; padding: 5px;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">IPC 4</td> <td style="padding: 5px;">A 23 L 1/29, /30, /305, 2/00, /38; A 23 C 9/133</td> </tr> <tr> <td style="padding: 5px;">US C1</td> <td style="padding: 5px;">426:18,20,48,49,52,330.3,590</td> </tr> </table> <div style="margin-top: 5px; font-size: x-small;"> Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸ </div> <div style="margin-top: 20px; padding: 10px;"> SE, NO, DK, FI classes as above. </div>			Classification System	Classification Symbols	IPC 4	A 23 L 1/29, /30, /305, 2/00, /38; A 23 C 9/133	US C1	426:18,20,48,49,52,330.3,590															
Classification System	Classification Symbols																						
IPC 4	A 23 L 1/29, /30, /305, 2/00, /38; A 23 C 9/133																						
US C1	426:18,20,48,49,52,330.3,590																						
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; text-align: left; padding: 5px;">Category ⁹</th> <th style="text-align: left; padding: 5px;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; text-align: left; padding: 5px;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">US, A, 4 056 637 (HAGIWARA et al) 1 November 1977 See claims 1-4</td> <td style="vertical-align: top; padding: 5px;">1,3,4,6,8, 9,11</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">US, A, 2 452 534 (G.A. JEFFREYS) 2 November 1948 See claim 1</td> <td style="vertical-align: top; padding: 5px;">1,3</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">US, A, 2 194 672 (C.M. PORTER) 26 March 1940 See claims 1,2</td> <td style="vertical-align: top; padding: 5px;">1,3,7</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">Patent Abstracts of Japan, Vol 10, No 112, C-342, abstract of JP 60-241848, publ 1985-11-30</td> <td style="vertical-align: top; padding: 5px;">1,3,9</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">Patent Abstracts of Japan, Vol 10, No 120, C-343, abstracts of JP 60-248131, publ 1985-12-07</td> <td style="vertical-align: top; padding: 5px;">1,3,9</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">Patent Abstracts of Japan, Vol 5, No 58, C-51, abstract of JP 56-11783 publ 1981-02-05 .../...</td> <td style="vertical-align: top; padding: 5px;">1,4,9</td> </tr> </table> <div style="margin-top: 10px; font-size: x-small;"> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div> </div>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	US, A, 4 056 637 (HAGIWARA et al) 1 November 1977 See claims 1-4	1,3,4,6,8, 9,11	X	US, A, 2 452 534 (G.A. JEFFREYS) 2 November 1948 See claim 1	1,3	X	US, A, 2 194 672 (C.M. PORTER) 26 March 1940 See claims 1,2	1,3,7	X	Patent Abstracts of Japan, Vol 10, No 112, C-342, abstract of JP 60-241848, publ 1985-11-30	1,3,9	X	Patent Abstracts of Japan, Vol 10, No 120, C-343, abstracts of JP 60-248131, publ 1985-12-07	1,3,9	X	Patent Abstracts of Japan, Vol 5, No 58, C-51, abstract of JP 56-11783 publ 1981-02-05 .../...	1,4,9
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																					
X	US, A, 4 056 637 (HAGIWARA et al) 1 November 1977 See claims 1-4	1,3,4,6,8, 9,11																					
X	US, A, 2 452 534 (G.A. JEFFREYS) 2 November 1948 See claim 1	1,3																					
X	US, A, 2 194 672 (C.M. PORTER) 26 March 1940 See claims 1,2	1,3,7																					
X	Patent Abstracts of Japan, Vol 10, No 112, C-342, abstract of JP 60-241848, publ 1985-11-30	1,3,9																					
X	Patent Abstracts of Japan, Vol 10, No 120, C-343, abstracts of JP 60-248131, publ 1985-12-07	1,3,9																					
X	Patent Abstracts of Japan, Vol 5, No 58, C-51, abstract of JP 56-11783 publ 1981-02-05 .../...	1,4,9																					
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search <div style="margin-top: 10px; text-align: center;">1989-05-10</div> </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report <div style="margin-top: 10px; text-align: center;">1989 -05- 3 0</div> </td> </tr> <tr> <td style="padding: 5px;"> International Searching Authority <div style="margin-top: 10px; text-align: center;">Swedish Patent Office</div> </td> <td style="padding: 5px;"> Signature of Authorized Officer <div style="margin-top: 10px; text-align: center;"> Inga-Karin Petersson </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="margin-top: 10px; text-align: center;">1989-05-10</div>	Date of Mailing of this International Search Report <div style="margin-top: 10px; text-align: center;">1989 -05- 3 0</div>	International Searching Authority <div style="margin-top: 10px; text-align: center;">Swedish Patent Office</div>	Signature of Authorized Officer <div style="margin-top: 10px; text-align: center;"> Inga-Karin Petersson </div>																	
Date of the Actual Completion of the International Search <div style="margin-top: 10px; text-align: center;">1989-05-10</div>	Date of Mailing of this International Search Report <div style="margin-top: 10px; text-align: center;">1989 -05- 3 0</div>																						
International Searching Authority <div style="margin-top: 10px; text-align: center;">Swedish Patent Office</div>	Signature of Authorized Officer <div style="margin-top: 10px; text-align: center;"> Inga-Karin Petersson </div>																						

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	Patent Abstracts of Japan, Vol 8, No 212, C-244, abstracts of JP 59-98672 publ 1984-06-07	1,3,9

